Recent Quotes

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

H1 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-09-08
REV		(EXPECTED)2021-09-08

Q1 2021		Est.		Actual		Surprise
EPS				-0.740
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
CYAD	Celyad Oncology	5.31	-0.04	-0.75%		79.7M

Celyad Oncology Frequently Asked Questions

How do I buy Celyad Oncology (CYAD) stock?

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Who are Celyad Oncology's (CYAD) competitors?

Other companies in Celyad Oncology’s space includes: PolarityTE (NASDAQ:PTE), Allena Pharmaceuticals (NASDAQ:ALNA), Advaxis (NASDAQ:ADXS), Cleveland BioLabs (NASDAQ:CBLI) and Addex Therapeutics (NASDAQ:ADXN).

What is the target price for Celyad Oncology (CYAD) stock?

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by HC Wainwright & Co. on May 10, 2021. The analyst firm set a price target for 17.00 expecting CYAD to rise to within 12 months (a possible 220.15% upside). 3 analyst firms have reported ratings in the last year.

Current Stock Price for Celyad Oncology (CYAD)?

The stock price for Celyad Oncology (NASDAQ: CYAD) is $5.31 last updated Today at 8:00:03 PM.

Does Celyad Oncology (CYAD) pay a dividend?

There are no upcoming dividends for Celyad Oncology.

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

Celyad Oncology’s H1 earnings are confirmed for after-market on September 8, 2021.

Is Celyad Oncology (CYAD) going to split?

There is no upcoming split for Celyad Oncology.

What sector and industry does Celyad Oncology (CYAD) operate in?

Celyad Oncology is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.